Thymopoietin, a polypeptide hormone isolated from thymic extracts, has been shown to affect immunoregulation by a number of mechanisms: induction of early T cell differentiation, inhibition of B cell differentiation, and modulation of mature lymphocytes.'-3 The pentapeptide TP-5, corresponding to residues 32-36 of thymopoietin, has been shown to retain the biological activity of thymopoietin and thus probably corresponds to the active site of the parent molecule.4 Preclinical animal studies with TP-5 have demonstrated a lack of toxicity at dosage levels up to 500 times that which is administered to humans. It is noteworthy that TP-5 is rapidly degraded to its component amino acids in human plasma (T 2-30 s) and that this may account for the lack of toxicity.5
One current hypothesis on the pathogenesis of rheumatoid arthritis (RA) has suggested a defect of immune regulation. centres collaborated to evaluate the effectiveness of TP-5 and to compare the efficacy of 2 dosage regimens.
Patients and methods

INVESTIGATION PLAN
This paper describes the results of 2 studies. In the first study, which was double-blind and ran from September 1978 to December 1979, TP-5 was administered at a dosage of 1 mg intramuscularly (IM) once weekly and was compared with a control group receiving intramuscular injections of 1 ml physiological saline at the same frequency. TP-5 was dissolved in physiological saline at 1 mg/ml. The study medications were specially packaged to ensure that the study was double-blind.
In the second study, which was open and ran from December 1978 to May 1980, 50 mg of TP-5 was administered intravenously (IV) once weekly. The controls of the first study were used for comparison.
PATIENTS
The study patients were outpatients with definite or classic rheumatoid arthritis of at least 6 months' duration, as defined by the American Rheumatism After 3 months of treatment neither the placebo group nor the TP-5 1 mg group showed statistically significant (p<005) improvement for any individual measurement. After 6 months of treatment the TP-5 1 mg group showed a statistically significant decrease in the number of swollen joints (p<0007), morning stiffness (p<00005), and pain (p<0 04). However, in the placebo group, a statistically significant decrease was also observed in the number of swollen joints (p<0 04), morning stiffness (p<0 03), and pain (p<0O006). No changes were observed in the ESR in either group, and the global scores reflected the overall lack of improvement seen in both groups.
After 3 months of treatment in the TP-5 50 mg group a statistically significant improvement was observed in all parameters (p<001) except the ESR. After 6 months .of treatment, this group showed a statistically significant improvement in all parameters (p<0005) except for the ESR. Table 3 shows the global response to treatment, as indicated by global scores and withdrawal for inefficacy. The overall results of treatment with 50 mg TP-5 intravenously were significantly better than with placebo (p=0005) and with 1 mg TP-5 
